Drug disposition in pathophysiological conditions

Current Drug Metabolism

Volumn 13, Issue 9, 2012, Pages 1327-1344

  Gandhi, Adarsh ^a   Moorthy, Bhagavatula ^b   Ghose, Romi ^a  

^a UNIVERSITY OF HOUSTON   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Cytokines; Drug metabolizing enzymes; Drug transporters; Inflammation; Pharmacokinetics; Toll like receptors

Indexed keywords

BCG VACCINE; CISPLATIN; CURCUMIN; CYTOCHROME P450 1A1; CYTOCHROME P450 1A2; CYTOCHROME P450 2B2; CYTOCHROME P450 2B6; DRUG METABOLIZING ENZYME; GENTAMICIN; GLUCOSE TRANSPORTER 2; HEXOBARBITAL; INTERLEUKIN 1BETA; MESSENGER RNA; MIDAZOLAM; MULTIDRUG RESISTANCE PROTEIN 1; MULTIDRUG RESISTANCE PROTEIN 2; NITRIC OXIDE; OATP1 PROTEIN; OCTAMER TRANSCRIPTION FACTOR 1; PHENAZONE; PROPRANOLOL; RUTOSIDE; SODIUM GLUCOSE COTRANSPORTER 2; SODIUM GLUCOSE COTRANSPORTER 3; SOTALOL; THEOPHYLLINE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANCOMYCIN; VERAPAMIL;

AREA UNDER THE CURVE; BACTERIAL INFECTION; CARDIOVASCULAR DISEASE; CITROBACTER RODENTIUM; DIABETES MELLITUS; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG METABOLISM; ENTERITIS; HEPATITIS C; HUMAN; IN VITRO STUDY; IN VIVO STUDY; KIDNEY PERFUSION; MAXIMUM PLASMA CONCENTRATION; NONALCOHOLIC FATTY LIVER; NONHUMAN; OBESITY; PROTEIN EXPRESSION; REVIEW; RHEUMATOID ARTHRITIS; SEPSIS; SIGNAL TRANSDUCTION; STOMACH CARCINOMA; UPREGULATION;

ANIMALS; ARTHRITIS, RHEUMATOID; CARDIOVASCULAR DISEASES; COMMUNICABLE DISEASES; DIABETES MELLITUS; DRUG THERAPY; FATTY LIVER; HUMANS; INFLAMMATION; MEMBRANE TRANSPORT PROTEINS; NEOPLASMS; OBESITY; PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS;

EID: 84868017737     PISSN: 13892002     EISSN: 18755453     Source Type: Journal    
DOI: 10.2174/138920012803341302     Document Type: Review

References (300)

1. Nebert, D.W.; Russell, D.W. Clinical importance of the cytochromes P450. Lancet. 2002, 360(9340), 1155-1162.
2. Guengerich, F.P. Cytochrome P-450 3A4: regulation and role in drug metabolism. Annu. Rev. Pharmacol. Toxicol., 1999, 39, 1-17.
3. Meyer, U.A. Overview of enzymes of drug metabolism. J. Pharmacokinet. Biopharm., 1996, 24(5), 449-459.
4. Jancova, P.; Anzenbacher, P.; Anzenbacherova, E. Phase II drug metabolizing enzymes. Biomed. Pap. Med. Fac. Univ. Palacky. Olomouc. Czech. Repub., 2010, 154(2), 103-116.
5. Giacomini, K.M.; Huang, S.M.; Tweedie, D.J.; Benet, L.Z.; Brouwer, K.L.; Chu, X.; Dahlin, A.; Evers, R.; Fischer, V.; Hillgren, K.M.; Hoffmaster, K.A.; Ishikawa, T.; Keppler, D.; Kim, R.B.; Lee, C.A.; Niemi, M.; Polli, J.W.; Sugiyama, Y.; Swaan, P.W.; Ware, J.A.; Wright, S.H.; Yee, S.W.; Zamek-Gliszczynski, M.J.; Zhang, L. Membrane transporters in drug development. Nat. Rev. Drug. Discov., 2010, 9(3), 215-236.
6. Klaassen, C.D.; Aleksunes, L.M. Xenobiotic, bile acid, and cholesterol transporters: function and regulation. Pharmacol. Rev., 2010, 62(1), 1-96.
7. Klaassen, C.D.; Lu, H. Xenobiotic transporters: ascribing function from gene knockout and mutation studies. Toxicol. Sci., 2008, 101(2), 186-196.
8. Mizuno, N.; Niwa, T.; Yotsumoto, Y.; Sugiyama, Y. Impact of drug transporter studies on drug discovery and development. Pharmacol. Rev., 2003, 55(3), 425-461.
9. Petrovic, V.; Teng, S.; Piquette-Miller, M. Regulation of drug transporters during infection and inflammation. Mol. Interv., 2007, 7(2), 99-111.
10. Borst, P.; Evers, R.; Kool, M.; Wijnholds, J. A family of drug transporters: the multidrug resistance-associated proteins. J. Natl. Cancer Inst., 2000, 92(16), 1295-1302.
11. Tanigawara, Y. Role of P-glycoprotein in drug disposition. Ther. Drug Monit., 2000, 22(1), 137-140.
12. Watkins, P.B. The barrier function of CYP3A4 and P-glycoprotein in the small bowel. Adv. Drug Deliv. Rev., 1997, 27(2-3), 161-170.
13. Ayrton, A.; Morgan, P. Role of transport proteins in drug absorption, distribution and excretion. Xenobiotica., 2001, 31(8-9), 469-497.
14. Kato, R. Drug metabolism under pathological and abnormal physiological states in animals and man. Xenobiotica., 1977, 7(1-2), 25-92.
15. Aitken, A.E.; Richardson, T.A.; Morgan, E.T. Regulation of drug-metabolizing enzymes and transporters in inflammation. Annu. Rev. Pharmacol. Toxicol., 2006, 46, 123-149.
16. Deng, X.; Luyendyk, J.P.; Ganey, P.E.; Roth, R.A. Inflammatory stress and idiosyncratic hepatotoxicity: hints from animal models. Pharmacol. Rev., 2009, 61(3), 262-282.
17. Pirmohamed, M.; James, S.; Meakin, S.; Green, C.; Scott, A.K.; Walley, T.J.; Farrar, K.; Park, B.K.; Breckenridge, A.M. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. BMJ, 2004, 329(7456), 15-19.
18. Dixon, R.L.; Hart, L.G.; Fouts, J.R. The metabolism of drugs by liver microsomes from alloxan-diabetic rats. J. Pharmacol. Exp. Ther., 1961, 133, 7-11.
19. Kato, R.; Frontino, G.; Vassanellip Decreased activities of liver microsomal drug-metabolizing enzymes in the rats bearing Walker carcinosarcoma. Experientia., 1963, 19, 31-32.
20. Klotz, U.; McHorse, T.S.; Wilkinson, G.R.; Schenker, S. The effect of cirrhosis on the disposition and elimination of meperidine in man. Clin. Pharmacol. Ther., 1974, 16(4), 667-675.
21. Kraemer, M.J.; Furukawa, C.T.; Koup, J.R.; Shapiro, G.G.; Pierson, W.E.; Bierman, C.W. Altered theophylline clearance during an influenza B outbreak. Pediatrics., 1982, 69(4), 476-480.
22. Kato, R.; Takanaka, A.; Oshima, T. Drug metabolism in tumor-bearing rats. II. In vivo metabolisms and effects of drugs in tumor-bearing rats. Jpn. J. Pharmacol., 1968, 18(2), 245-254.
23. Zordoky, B.N.; El-Kadi, A.O. Role of NF-kappaB in the regulation of cytochrome P450 enzymes. Curr. Drug. Metab., 2009, 10(2), 164-178.
24. Gonzalez, F.J.; Lee, Y.H. Constitutive expression of hepatic cytochrome P450 genes. FASEB J., 1996, 10(10), 1112-1117.
25. Xie, W. Nuclear Receptors in Drug Metabolism. 1 edn. John Wiley & Sons, Inc.: Hoboken, NJ 2008.
26. Tirona, R.G.; Lee, W.; Leake, B.F.; Lan, L.B.; Cline, C.B.; Lamba, V.; Parviz, F.; Duncan, S.A.; Inoue, Y.; Gonzalez, F.J.; Schuetz, E.G.; Kim, R.B. The orphan nuclear receptor HNF4alpha determines PXR-and CAR-mediated xenobiotic induction of CYP3A4. Nat. Med., 2003, 9(2), 220-224.
27. Wichterman, K.A.; Baue, A.E.; Chaudry, I.H. Sepsis and septic shock - a review of laboratory models and a proposal. J. Surg. Res., 1980, 29(2), 189-201.
28. Higgins, L.M.; Frankel, G.; Douce, G.; Dougan, G.; MacDonald, T.T. Citrobacter rodentium infection in mice elicits a mucosal Th1 cytokine response and lesions similar to those in murine inflammatory bowel disease. Infect Immun., 1999, 67(6), 3031-3039.
29. Godellas, C.V.; Williams, J.F.; Fabri, P.J. Mixed-function oxidase activity in sepsis. J. Surg. Res., 1995, 59(6), 783-786.
30. Chaluvadi, M.R.; Kinloch, R.D.; Nyagode, B.A.; Richardson, T.A.; Raynor, M.J.; Sherman, M.; Antonovic, L.; Strobel, H.W.; Dillehay, D.L.; Morgan, E.T. Regulation of hepatic cytochrome P450 expression in mice with intestinal or systemic infections of citrobacter rodentium. Drug Metab. Dispos., 2009, 37(2), 366-374.
31. Monshouwer, M.; Witkamp, R.F.; Nijmeijer, S.M.; Pijpers, A.; Verheijden, J.H.; Van Miert, A.S. Selective effects of a bacterial infection (Actinobacillus pleuropneumoniae) on the hepatic clearances of caffeine, antipyrine, paracetamol, and indocyanine green in the pig. Xenobiotica., 1995, 25(5), 491-499.
32. Martin, G.S.; Mannino, D.M.; Eaton, S.; Moss, M. The epidemiology of sepsis in the United States from 1979 through 2000. N. Engl. J. Med., 2003, 348(16), 1546-1554.
33. Garcia Del Busto Cano, E.; Renton, K.W. Modulation of hepatic cytochrome P450 during Listeria monocytogenes infection of the brain. J. Pharm. Sci., 2003, 92(9), 1860-1868.
34. Ginsburg, I. Role of lipoteichoic acid in infection and inflammation. Lancet Infect. Dis., 2002, 2(3), 171-179.
35. Leemans, J.C.; Vervoordeldonk, M.J.; Florquin, S.; van Kessel, K.P.; van der Poll, T. Differential role of interleukin-6 in lung inflammation induced by lipoteichoic acid and peptidoglycan from Staphylococcus aureus. Am. J. Respir. Crit. Care Med., 2002, 165(10), 1445-1450.
36. Sewer, M.B.; Koop, D.R.; Morgan, E.T. Endotoxemia in rats is associated with induction of the P4504A subfamily and suppression of several other forms of cytochrome P450. Drug Metab. Dispos., 1996, 24(4), 401-407.
37. Ghose, R.; White, D.; Guo, T.; Vallejo, J.; Karpen, S.J. Regulation of hepatic drug-metabolizing enzyme genes by Toll-like receptor 4 signaling is independent of Toll-interleukin 1 receptor domain-containing adaptor protein. Drug Metab. Dispos., 2008, 36(1), 95-101.
38. Shimamoto, Y.; Kitamura, H.; Hoshi, H.; Kazusaka, A.; Funae, Y.; Imaoka, S.; Saito, M.; Fujita, S. Differential alterations in levels of hepatic microsomal cytochrome P450 isozymes following intrac-erebroventricular injection of bacterial lipopolysaccharide in rats. Arch. Toxicol., 1998, 72(8), 492-498.
39. Ghose, R.; Guo, T.; Haque, N. Regulation of gene expression of hepatic drug metabolizing enzymes and transporters by the Tolllike receptor 2 ligand, lipoteichoic acid. Arch Biochem. Biophys., 2009, 481(1), 123-130.
40. Dietrich, C.G.; de Waart, D.R.; Ottenhoff, R.; Schoots, I.G.; Elferink, R.P. Increased bioavailability of the food-derived carcinogen 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine in MRP2-deficient rats. Mol. Pharmacol., 2001, 59(5), 974-980.
41. Piquette-Miller, M.; Pak, A.; Kim, H.; Anari, R.; Shahzamani, A. Decreased expression and activity of P-glycoprotein in rat liver during acute inflammation. Pharm. Res., 1998, 15(5), 706-711.
42. Sukhai, M.; Yong, A.; Kalitsky, J.; Piquette-Miller, M. Inflammation and interleukin-6 mediate reductions in the hepatic expression and transcription of the mdr1a and mdr1b Genes. Mol. Cell Biol. Res. Commun., 2000, 4(4), 248-256.
43. Hartmann, G.; Kim, H.; Piquette-Miller, M. Regulation of the hepatic multidrug resistance gene expression by endotoxin and inflammatory cytokines in mice. Int. Immunopharmacol., 2001, 1(2), 189-199.
44. Vos, T.A.; Hooiveld, G.J.; Koning, H.; Childs, S.; Meijer, D.K.; Moshage, H.; Jansen, P.L.; Muller, M. Up-regulation of the multidrug resistance genes, Mrp1 and Mdr1b, and down-regulation of the organic anion transporter, Mrp2, and the bile salt transporter, Spgp, in endotoxemic rat liver. Hepatology. 1998, 28(6), 1637-1644.
45. Hewett, J.A.; Roth, R.A. Hepatic and extrahepatic pathobiology of bacterial lipopolysaccharides. Pharmacol. Rev., 1993, 45(4), 382-411.
46. Ros, J.E.; Schuetz, J.D.; Geuken, M.; Streetz, K.; Moshage, H.; Kuipers, F.; Manns, M.P.; Jansen, P.L.; Trautwein, C.; Muller, M. Induction of Mdr1b expression by tumor necrosis factor-alpha in rat liver cells is independent of p53 but requires NF-kappaB signaling. Hepatology., 2001, 33(6), 1425-1431.
47. Zhou, G.; Kuo, M.T. NF-kappaB-mediated induction of mdr1b expression by insulin in rat hepatoma cells. J. Biol. Chem., 1997, 272(24), 15174-15183.
48. Hartmann, G.; Vassileva, V.; Piquette-Miller, M. Impact of endotoxin-induced changes in P-glycoprotein expression on disposition of doxorubicin in mice. Drug Metab. Dispos., 2005, 33(6), 820-828.
49. Wang, J.H.; Scollard, D.A.; Teng, S.; Reilly, R.M.; Piquette-Miller, M. Detection of P-glycoprotein activity in endotoxemic rats by 99mTc-sestamibi imaging. J. Nucl. Med., 2005, 46(9), 1537-1545.
50. Goralski, K.B.; Hartmann, G.; Piquette-Miller, M.; Renton, K.W. Downregulation of mdr1a expression in the brain and liver during CNS inflammation alters the in vivo disposition of digoxin. Br. J. Pharmacol., 2003, 139(1), 35-48.
51. Kalitsky-Szirtes, J.; Shayeganpour, A.; Brocks, D.R.; Piquette-Miller, M. Suppression of drug-metabolizing enzymes and efflux transporters in the intestine of endotoxin-treated rats. Drug Metab. Dispos., 2004, 32(1), 20-27.
52. Hartmann, G.; Cheung, A.K.; Piquette-Miller, M. Inflammatory cytokines, but not bile acids, regulate expression of murine hepatic anion transporters in endotoxemia. J. Pharmacol. Exp. Ther., 2002, 303(1), 273-281.
53. Tang, W.; Yi, C.; Kalitsky, J.; Piquette-Miller, M. Endotoxin downregulates hepatic expression of P-glycoprotein and MRP2 in 2-acetylaminofluorene-treated rats. Mol. Cell Biol. Res. Commun., 2000, 4(2), 90-97.
54. Li, N.; Choudhuri, S.; Cherrington, N.J.; Klaassen, C.D. Down-regulation of mouse organic anion-transporting polypeptide 4 (Oatp4; Oatp1b2; Slc21a10) mRNA by lipopolysaccharide through the toll-like receptor 4 (TLR4). Drug Metab. Dispos., 2004, 32(11), 1265-1271.
55. Cherrington, N.J.; Slitt, A.L.; Li, N.; Klaassen, C.D. Lipopolysac-charide-mediated regulation of hepatic transporter mRNA levels in rats. Drug Metab. Dispos., 2004, 32(7), 734-741.
56. Green, R.M.; Beier, D.; Gollan, J.L. Regulation of hepatocyte bile salt transporters by endotoxin and inflammatory cytokines in rodents. Gastroenterology., 1996, 111(1), 193-198.
57. Bauer, B.; Hartz, A.M.; Miller, D.S. Tumor necrosis factor alpha and endothelin-1 increase P-glycoprotein expression and transport activity at the blood-brain barrier. Mol. Pharmacol., 2007, 71(3), 667-675.
58. Hartz, A.M.; Bauer, B.; Fricker, G.; Miller, D.S. Rapid modulation of P-glycoprotein-mediated transport at the blood-brain barrier by tumor necrosis factor-alpha and lipopolysaccharide. Mol. Pharmacol., 2006, 69(2), 462-470.
59. Nones, K.; Dommels, Y.E.; Martell, S.; Butts, C.; McNabb, W.C.; Park, Z.A.; Zhu, S.; Hedderley, D.; Barnett, M.P.; Roy, N.C. The effects of dietary curcumin and rutin on colonic inflammation and gene expression in multidrug resistance gene-deficient (mdr1a-/-) mice, a model of inflammatory bowel diseases. Br. J. Nutr., 2009, 101(2), 169-181.
60. Schmidt, C.; Hocherl, K.; Bucher, M. Regulation of renal glucose transporters during severe inflammation. Am. J. Physiol. Renal Physiol., 2007, 292(2), F804-811.
61. Gray, J.D.; Renton, K.W.; Hung, O.R. Depression of theophylline elimination following BCG vaccination. Br. J. Clin. Pharmacol., 1983, 16(6), 735-737.
62. Sonne, J.; Dossing, M.; Loft, S.; Andreasen, P.B. Antipyrine clearance in pneumonia. Clin. Pharmacol. Ther., 1985, 37(6), 701-704.
63. Modric, S.; Webb, A.I.; Derendorf, H. Pharmacokinetics and pharmacodynamics of tilmicosin in sheep and cattle. J. Vet. Pharmacol. Ther., 1998, 21(6), 444-452.
64. Ishikawa, M.; Ohzeki, R.; Takayanagi, Y.; Sasaki, K. Potentiation of cisplatin lethality by bacterial lipopolysaccharide pretreatment in mice. Res. Commun. Chem. Pathol. Pharmacol., 1990, 70(3), 375-378.
65. Hasegawa, T.; Nadai, M.; Wang, L.; Haghgoo, S.; Nabeshima, T.; Kato, N. Influence of endotoxin and lipid A on the renal handling and accumulation of gentamicin in rats. Biol. Pharm. Bull., 1994, 17(12), 1651-1655.
66. Shedlofsky, S.I.; Israel, B.C.; McClain, C.J.; Hill, D.B.; Blouin, R.A. Endotoxin administration to humans inhibits hepatic cytochrome P450-mediated drug metabolism. J. Clin. Invest., 1994, 94(6), 2209-2214.
67. Gous, A.G.; Dance, M.D.; Lipman, J.; Luyt, D.K.; Mathivha, R.; Scribante, J. Changes in vancomycin pharmacokinetics in critically ill infants. Anaesth. Intensive Care., 1995, 23(6), 678-682.
68. Pinder, M.; Bellomo, R.; Lipman, J. Pharmacological principles of antibiotic prescription in the critically ill. Anaesth. Intensive Care., 2002, 30(2), 134-144.
69. Frapolli, R.; Zucchetti, M.; Sessa, C.; Marsoni, S.; Vigano, L.; Locatelli, A.; Rulli, E.; Compagnoni, A.; Bello, E.; Pisano, C.; Carminati, P.; D'Incalci, M. Clinical pharmacokinetics of the new oral camptothecin gimatecan: the inter-patient variability is related to alpha1-acid glycoprotein plasma levels. Eur. J. Cancer., 2010, 46(3), 505-516.
70. Mayo, P.R.; Skeith, K.; Russell, A.S.; Jamali, F. Decreased dromotropic response to verapamil despite pronounced increased drug concentration in rheumatoid arthritis. Br. J. Clin. Pharmacol., 2000, 50(6), 605-613.
71. Guirguis, M.S.; Jamali, F. Disease-drug interaction: Reduced response to propranolol despite increased concentration in the rat with inflammation. J. Pharm. Sci., 2003, 92(5), 1077-1084.
72. Mannering, G.J.; Deloria, L.B. The pharmacology and toxicology of the interferons: an overview. Annu. Rev. Pharmacol. Toxicol., 1986, 26, 455-515.
73. Corbett, T.H.; Nettesheim, P. Effect of PR-8 viral respiratory infection of benz [a]pyrene hydroxylase activity in BALB/c mice. J. Natl. Cancer Inst., 1973, 50(3), 779-782.
74. Singh, G.; Renton, K.W. Interferon-mediated depression of cytochrome P-450-dependent drug biotransformation. Mol. Pharmacol., 1981, 20(3), 681-684.
75. Renton, K.W. Depression of hepatic cytochrome P-450-dependent mixed function oxidases during infection with encephalomyocarditis virus. Biochem. Pharmacol., 1981, 30(16), 2333-2336.
76. Schoene, B.; Fleischmann, R.A.; Remmer, H.; von Oldershausen, H.F. Determination of drug metabolizing enzymes in needle biopsies of human liver. Eur. J. Clin. Pharmacol., 1972, 4(2), 65-73.
77. Wilkinson, G.R. The effects of diet, aging and disease-states on presystemic elimination and oral drug bioavailability in humans. Adv. Drug Deliv. Rev., 1997, 27(2-3), 129-159.
78. Lee, B.L.; Wong, D.; Benowitz, N.L.; Sullam, P.M. Altered patterns of drug metabolism in patients with acquired immunodeficiency syndrome. Clin. Pharmacol. Ther., 1993, 53(5), 529-535.
79. Kikuchi, R.; McCown, M.; Olson, P.; Tateno, C.; Morikawa, Y.; Katoh, Y.; Bourdet, D.L.; Monshouwer, M.; Fretland, A.J. Effect of hepatitis C virus infection on the mRNA expression of drug transporters and cytochrome p450 enzymes in chimeric mice with humanized liver. Drug Metab. Dispos., 2010, 38(11), 1954-1961.
80. Callahan, S.M.; Ming, X.; Lu, S.K.; Brunner, L.J.; Croyle, M.A. Considerations for use of recombinant adenoviral vectors: dose effect on hepatic cytochromes P450. J. Pharmacol. Exp. Ther., 2005, 312(2), 492-501.
81. Le, H.T.; Boquet, M.P.; Clark, E.A.; Callahan, S.M.; Croyle, M.A. Renal pathophysiology after systemic administration of recombinant adenovirus: changes in renal cytochromes P450 based on vector dose. Hum. Gene Ther., 2006, 17(11), 1095-1111.
82. Jones, A.E.; Brown, K.C.; Werner, R.E.; Gotzkowsky, K.; Gaedigk, A.; Blake, M.; Hein, D.W.; van der Horst, C.; Kashuba, A.D. Variability in drug metabolizing enzyme activity in HIV-infected patients. Eur. J. Clin. Pharmacol., 2010, 66(5), 475-485.
83. Ronaldson, P.T.; Ashraf, T.; Bendayan, R. Regulation of multidrug resistance protein 1 by tumor necrosis factor alpha in cultured glial cells: involvement of nuclear factor-kappaB and c-Jun N-terminal kinase signaling pathways. Mol. Pharmacol., 2010, 77(4), 644-659.
84. Ronaldson, P.T.; Bendayan, R. HIV-1 viral envelope glycoprotein gp120 triggers an inflammatory response in cultured rat astrocytes and regulates the functional expression of P-glycoprotein. Mol. Pharmacol., 2006, 70(3), 1087-1098.
85. Giraud, C.; Manceau, S.; Decleves, X.; Goffinet, F.; Morini, J.P.; Chappuy, H.; Batteux, F.; Chouzenoux, S.; Yousif, S.; Scherrmann, J.M.; Blanche, S.; Treluyer, J.M. Influence of development, HIV infection, and antiretroviral therapies on the gene expression profiles of ABC transporters in human lymphocytes. J. Clin. Pharmacol., 2010, 50(2), 226-230.
86. Gollapudi, S.; Gupta, S. Human immunodeficiency virus I-induced expression of P-glycoprotein. Biochem. Biophys. Res. Commun., 1990, 171(3), 1002-1007.
87. Andreana, A.; Gollapudi, S.; Gupta, S. Salmonella typhimurium induces expression of P glycoprotein (multidrug resistance 1 gene product) in a promonocytic cell line chronically infected with human immunodeficiency virus type 1. J. Infect. Dis., 1994, 169(4), 760-765.
88. Petrovic, V.; Piquette-Miller, M. Impact of polyinosinic/polycytidylic acid on placental and hepatobiliary drug transporters in pregnant rats. Drug Metab. Dispos., 2010, 38(10), 1760-1766.
89. Ogasawara, K.; Terada, T.; Katsura, T.; Hatano, E.; Ikai, I.; Yamaoka, Y.; Inui, K. Hepatitis C virus-related cirrhosis is a major determinant of the expression levels of hepatic drug transporters. Drug Metab. Pharmacokinet., 2010, 25(2), 190-199.
90. Le Vee, M.; Jouan, E.; Moreau, A.; Fardel, O. Regulation of drug transporter mRNA expression by interferon-gamma in primary human hepatocytes. Fundam. Clin. Pharmacol., 2010, 25(1), 99-103.
91. Goodwin, S.D.; Gallis, H.A.; Chow, A.T.; Wong, F.A.; Flor, S.C.; Bartlett, J.A. Pharmacokinetics and safety of levofloxacin in patients with human immunodeficiency virus infection. Antimicrob. Agents Chemother., 1994, 38(4), 799-804.
92. Tett, S.; Moore, S.; Ray, J. Pharmacokinetics and bioavailability of fluconazole in two groups of males with human immunodeficiency virus (HIV) infection compared with those in a group of males without HIV infection. Antimicrob. Agents Chemother., 1995, 39(8), 1835-1841.
93. Bica, I.; McGovern, B.; Dhar, R.; Stone, D.; McGowan, K.; Scheib, R.; Snydman, D.R. Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection. Clin. Infect. Dis., 2001, 32(3), 492-497.
94. Regazzi, M.; Maserati, R.; Villani, P.; Cusato, M.; Zucchi, P.; Briganti, E.; Roda, R.; Sacchelli, L.; Gatti, F.; Delle Foglie, P.; Nardini, G.; Fabris, P.; Mori, F.; Castelli, P.; Testa, L. Clinical pharmacokinetics of nelfinavir and its metabolite M8 in human immunodeficiency virus (HIV)-positive and HIV-hepatitis C virus-coinfected subjects. Antimicrob. Agents Chemother., 2005, 49(2), 643-649.
95. Veronese, L.; Rautaureau, J.; Sadler, B.M.; Gillotin, C.; Petite, J.P.; Pillegand, B.; Delvaux, M.; Masliah, C.; Fosse, S.; Lou, Y.; Stein, D.S. Single-dose pharmacokinetics of amprenavir, a human immunodeficiency virus type 1 protease inhibitor, in subjects with normal or impaired hepatic function. Antimicrob. Agents Chemother., 2000, 44(4), 821-826.
96. Wyles, D.L.; Gerber, J.G. Antiretroviral drug pharmacokinetics in hepatitis with hepatic dysfunction. Clin. Infect. Dis., 2005, 40(1), 174-181.
97. Wonganan, P.; Zamboni, W.C.; Strychor, S.; Dekker, J.D.; Croyle, M.A. Drug-virus interaction: effect of administration of recombinant adenoviruses on the pharmacokinetics of docetaxel in a rat model. Cancer Gene Ther., 2009, 16(5), 405-414.
98. Scott, M.J.; Liu, S.; Shapiro, R.A.; Vodovotz, Y.; Billiar, T.R. Endotoxin uptake in mouse liver is blocked by endotoxin pretreatment through a suppressor of cytokine signaling-1-dependent mechanism. Hepatology., 2009, 49(5), 1695-1708.
99. Aliprantis, A.O.; Yang, R.B.; Mark, M.R.; Suggett, S.; Devaux, B.; Radolf, J.D.; Klimpel, G.R.; Godowski, P.; Zychlinsky, A. Cell activation and apoptosis by bacterial lipoproteins through toll-like receptor-2. Science., 1999, 285(5428), 736-739.
100. Takeuchi, O.; Hoshino, K.; Kawai, T.; Sanjo, H.; Takada, H.; Ogawa, T.; Takeda, K.; Akira, S. Differential roles of TLR2 and TLR4 in recognition of gram-negative and gram-positive bacterial cell wall components. Immunity., 1999, 11(4), 443-451.
101. Ferrari, L.; Peng, N.; Halpert, J.R.; Morgan, E.T. Role of nitric oxide in down-regulation of CYP2B1 protein, but not RNA, in primary cultures of rat hepatocytes. Mol. Pharmacol., 2001, 60(1), 209-216.
102. Ghose, R.; Guo, T.; Vallejo, J.G.; Gandhi, A. Differential role of Toll-interleukin 1 receptor domain-containing adaptor protein in Toll-like receptor 2-mediated regulation of gene expression of hepatic cytokines and drug-metabolizing enzymes. Drug Metab. Dispos., 2011, 39(5), 874-881.
103. Kagan, J.C.; Medzhitov, R. Phosphoinositide-mediated adaptor recruitment controls Toll-like receptor signaling. Cell., 2006, 125(5), 943-955.
104. Barker, C.W.; Fagan, J.B.; Pasco, D.S. Interleukin-1 beta suppresses the induction of P4501A1 and P4501A2 mRNAs in isolated hepatocytes. J. Biol. Chem., 1992, 267(12), 8050-8055.
105. Muntane-Relat, J.; Ourlin, J.C.; Domergue, J.; Maurel, P. Differential effects of cytokines on the inducible expression of CYP1A1, CYP1A2, and CYP3A4 in human hepatocytes in primary culture. Hepatology., 1995, 22(4 Pt 1), 1143-1153.
106. Milosevic, N.; Schawalder, H.; Maier, P. Kupffer cell-mediated differential down-regulation of cytochrome P450 metabolism in rat hepatocytes. Eur. J. Pharmacol., 1999, 368(1), 75-87.
107. Lee, G.; Piquette-Miller, M. Cytokines alter the expression and activity of the multidrug resistance transporters in human hepatoma cell lines; analysis using RT-PCR and cDNA microarrays. J. Pharm. Sci., 2003, 92(11), 2152-2163.
108. Le Vee, M.; Gripon, P.; Stieger, B.; Fardel, O. Down-regulation of organic anion transporter expression in human hepatocytes exposed to the proinflammatory cytokine interleukin 1beta. Drug Metab. Dispos., 2008, 36(2), 217-222.
109. Warren, G.W.; Poloyac, S.M.; Gary, D.S.; Mattson, M.P.; Blouin, R.A. Hepatic cytochrome P-450 expression in tumor necrosis factor-alpha receptor (p55/p75) knockout mice after endotoxin administration. J. Pharmacol. Exp. Ther., 1999, 288(3), 945-950.
110. Warren, G.W.; van Ess, P.J.; Watson, A.M.; Mattson, M.P.; Blouin, R.A. Cytochrome P450 and antioxidant activity in interleukin-6 knockout mice after induction of the acute-phase response. J. Interferon. Cytokine Res., 2001, 21(10), 821-826.
111. Kinloch, R.D.; Lee, C.M.; van Rooijen, N.; Morgan, E.T. Selective role for tumor necrosis factor-alpha, but not interleukin-1 or Kupffer cells, in down-regulation of CYP3A11 and CYP3A25 in livers of mice infected with a noninvasive intestinal pathogen. Biochem. Pharmacol., 2011, 82(3), 312-321.
112. Abdel-Razzak, Z.; Loyer, P.; Fautrel, A.; Gautier, J.C.; Corcos, L.; Turlin, B.; Beaune, P.; Guillouzo, A. Cytokines down-regulate expression of major cytochrome P-450 enzymes in adult human hepatocytes in primary culture. Mol. Pharmacol., 1993, 44(4), 707-715.
113. Aitken, A.E.; Morgan, E.T. Gene-specific effects of inflammatory cytokines on cytochrome P450 2C, 2B6 and 3A4 mRNA levels in human hepatocytes. Drug Metab. Dispos., 2007, 35(9), 1687-1693.
114. Lee, G.; Piquette-Miller, M. Influence of IL-6 on MDR and MRP-mediated multidrug resistance in human hepatoma cells. Can. J. Physiol. Pharmacol., 2001, 79(10), 876-884.
115. Vee, M.L.; Lecureur, V.; Stieger, B.; Fardel, O. Regulation of drug transporter expression in human hepatocytes exposed to the proin-flammatory cytokines tumor necrosis factor-alpha or interleukin-6. Drug Metab. Dispos., 2009, 37(3), 685-693.
116. Lickteig, A.J.; Slitt, A.L.; Arkan, M.C.; Karin, M.; Cherrington, N.J. Differential regulation of hepatic transporters in the absence of tumor necrosis factor-alpha, interleukin-1beta, interleukin-6, and nuclear factor-kappaB in two models of cholestasis. Drug Metab. Dispos., 2007, 35(3), 402-409.
117. Poller, B.; Drewe, J.; Krahenbuhl, S.; Huwyler, J.; Gutmann, H. Regulation of BCRP (ABCG2) and P-glycoprotein (ABCB1) by cytokines in a model of the human blood-brain barrier. Cell Mol. Neurobiol., 2010, 30(1), 63-70.
118. Hirsch-Ernst, K.I.; Ziemann, C.; Foth, H.; Kozian, D.; Schmitz-Salue, C.; Kahl, G.F. Induction of mdr1b mRNA and P-glycoprotein expression by tumor necrosis factor alpha in primary rat hepatocyte cultures. J. Cell Physiol., 1998, 176(3), 506-515.
119. McRae, M.P.; Brouwer, K.L.; Kashuba, A.D. Cytokine regulation of P-glycoprotein. Drug Metab. Rev., 2003, 35(1), 19-33.
120. Morris, S.M., Jr.; Billiar, T.R. New insights into the regulation of inducible nitric oxide synthesis. Am. J. Physiol., 1994, 266(6 Pt 1), E829-839.
121. Carlson, T.J.; Billings, R.E. Role of nitric oxide in the cytokine-mediated regulation of cytochrome P-450. Mol. Pharmacol., 1996, 49(5), 796-801.
122. Sewer, M.B.; Morgan, E.T. Nitric oxide-independent suppression of P450 2C11 expression by interleukin-1beta and endotoxin in primary rat hepatocytes. Biochem. Pharmacol., 1997, 54(6), 729-737.
123. Monshouwer, M.; Witkamp, R.F.; Nujmeijer, S.M.; Van Amsterdam, J.G.; Van Miert, A.S. Suppression of cytochrome P450-and UDP glucuronosyl transferase-dependent enzyme activities by proinflammatory cytokines and possible role of nitric oxide in primary cultures of pig hepatocytes. Toxicol. Appl. Pharmacol., 1996, 137(2), 237-244.
124. Heemskerk, S.; van Koppen, A.; van den Broek, L.; Poelen, G.J.; Wouterse, A.C.; Dijkman, H.B.; Russel, F.G.; Masereeuw, R. Nitric oxide differentially regulates renal ATP-binding cassette transporters during endotoxemia. Pflugers. Arch., 2007, 454(2), 321-334.
125. Heemskerk, S.; Wouterse, A.C.; Russel, F.G.; Masereeuw, R. Nitric oxide down-regulates the expression of organic cation transporters (OCT) 1 and 2 in rat kidney during endotoxemia. Eur. J. Pharmacol., 2008, 584(2-3), 390-397.
126. Abdulla, D.; Goralski, K.B.; Del Busto Cano, E.G.; Renton, K.W. The signal transduction pathways involved in hepatic cytochrome P450 regulation in the rat during a lipopolysaccharide-induced model of central nervous system inflammation. Drug Metab. Dispos., 2005, 33(10), 1521-1531.
127. Gilmore, T.D. Introduction to NF-kappaB: players, pathways, perspectives. Oncogene., 2006, 25(51), 6680-6684.
128. Pascussi, J.M.; Dvorak, Z.; Gerbal-Chaloin, S.; Assenat, E.; Maurel, P.; Vilarem, M.J. Pathophysiological factors affecting CAR gene expression. Drug Metab. Rev., 2003, 35(4), 255-268.
129. Gu, X.; Ke, S.; Liu, D.; Sheng, T.; Thomas, P.E.; Rabson, A.B.; Gallo, M.A.; Xie, W.; Tian, Y. Role of NF-kappaB in regulation of PXR-mediated gene expression: a mechanism for the suppression of cytochrome P-450 3A4 by proinflammatory agents. J. Biol. Chem., 2006, 281(26), 17882-17889.
130. Adam-Stitah, S.; Penna, L.; Chambon, P.; Rochette-Egly, C. Hyperphosphorylation of the retinoid X receptor alpha by activated c-Jun NH2-terminal kinases. J. Biol. Chem., 1999, 274(27), 18932-18941.
131. Yu, R.; Lei, W.; Mandlekar, S.; Weber, M.J.; Der, C.J.; Wu, J.; Kong, A.N. Role of a mitogen-activated protein kinase pathway in the induction of phase II detoxifying enzymes by chemicals. J. Biol. Chem., 1999, 274(39), 27545-27552.
132. Zhou, J.; Liu, M.; Aneja, R.; Chandra, R.; Lage, H.; Joshi, H.C. Reversal of P-glycoprotein-mediated multidrug resistance in cancer cells by the c-Jun NH2-terminal kinase. Cancer Res., 2006, 66(1), 445-452.
133. Synold, T.W.; Dussault, I.; Forman, B.M. The orphan nuclear receptor SXR coordinately regulates drug metabolism and efflux. Nat. Med., 2001, 7(5), 584-590.
134. Ghose, R.; Zimmerman, T.L.; Thevananther, S.; Karpen, S.J. Endotoxin leads to rapid subcellular re-localization of hepatic RXRal-pha: A novel mechanism for reduced hepatic gene expression in inflammation. Nucl. Recept., 2004, 2(1), 4.
135. Richardson, T.A.; Morgan, E.T. Hepatic cytochrome P450 gene regulation during endotoxin-induced inflammation in nuclear receptor knockout mice. J. Pharmacol. Exp. Ther., 2005, 314(2), 703-709.
136. Teng, S.; Piquette-Miller, M. The involvement of the pregnane X receptor in hepatic gene regulation during inflammation in mice. J. Pharmacol. Exp. Ther., 2005, 312(2), 841-848.
137. Kacevska, M.; Downes, M.R.; Sharma, R.; Evans, R.M.; Clarke, S.J.; Liddle, C.; Robertson, G.R. Extrahepatic cancer suppresses nuclear receptor-regulated drug metabolism. Clin. Cancer Res., 2011, 17(10), 3170-3180.
138. Hanada, K.; Nakai, K.; Tanaka, H.; Suzuki, F.; Kumada, H.; Ohno, Y.; Ozawa, S.; Ogata, H. Effect of nuclear receptor downregulation on hepatic expression of cytochrome P450 and transporters in chronic hepatitis C in association with fibrosis development. Drug Metab. Pharmacokinet., 2011,
139. Jover, R.; Bort, R.; Gomez-Lechon, M.J.; Castell, J.V. Downregulation of human CYP3A4 by the inflammatory signal interleukin-6: molecular mechanism and transcription factors involved. Faseb. J., 2002, 16(13), 1799-1801.
140. Charles, K.A.; Rivory, L.P.; Brown, S.L.; Liddle, C.; Clarke, S.J.; Robertson, G.R. Transcriptional repression of hepatic cytochrome P450 3A4 gene in the presence of cancer. Clin. Cancer Res., 2006, 12(24), 7492-7497.
141. DeLoia, J.A.; Zamboni, W.C.; Jones, J.M.; Strychor, S.; Kelley, J.L.; Gallion, H.H. Expression and activity of taxane-metabolizing enzymes in ovarian tumors. Gynecol. Oncol., 2008, 108(2), 355-360.
142. Ly, L.H.; Zhao, X.Y.; Holloway, L.; Feldman, D. Liarozole acts synergistically with 1alpha, 25-dihydroxyvitamin D3 to inhibit growth of DU 145 human prostate cancer cells by blocking 24-hydroxylase activity. Endocrinology., 1999, 140(5), 2071-2076.
143. Sharma, R.; Kacevska, M.; London, R.; Clarke, S.J.; Liddle, C.; Robertson, G. Downregulation of drug transport and metabolism in mice bearing extra-hepatic malignancies. Br. J. Cancer., 2008, 98(1), 91-97.
144. Morgan, E.T.; Goralski, K.B.; Piquette-Miller, M.; Renton, K.W.; Robertson, G.R.; Chaluvadi, M.R.; Charles, K.A.; Clarke, S.J.; Kacevska, M.; Liddle, C.; Richardson, T.A.; Sharma, R.; Sinal, C.J. Regulation of drug-metabolizing enzymes and transporters in infection, inflammation, and cancer. Drug Metab. Dispos., 2008, 36(2), 205-216.
145. Williams, J.A.; Phillips, D.H. Mammary expression of xenobiotic metabolizing enzymes and their potential role in breast cancer. Cancer Res., 2000, 60(17), 4667-4677.
146. Kim, S.J.; Kang, H.S.; Jung, S.Y.; Min, S.Y.; Lee, S.; Kim, S.W.; Kwon, Y.; Lee, K.S.; Shin, K.H.; Ro, J. Methylation patterns of genes coding for drug-metabolizing enzymes in tamoxifen-resistant breast cancer tissues. J. Mol. Med. (Berl)., 2010, 88(11), 1123-1131.
147. Dupret, J.M.; Goodfellow, G.H.; Janezic, S.A.; Grant, D.M. Structure-function studies of human arylamine N-acetyltransferases NAT1 and NAT2. Functional analysis of recombinant NAT1/NAT2 chimeras expressed in Escherichia coli. J. Biol. Chem., 1994, 269(43), 26830-26835.
148. Butcher, N.J.; Boukouvala, S.; Sim, E.; Minchin, R.F. Pharmaco-genetics of the arylamine N-acetyltransferases. Pharmacogenomics J., 2002, 2(1), 30-42.
149. Minchin, R.F. Acetylation of p-aminobenzoylglutamate, a folic acid catabolite, by recombinant human arylamine N-acetyltransferase and U937 cells. Biochem. J., 1995, 307 (Pt 1), 1-3.
150. Robinson, L.J.; Roberts, W.K.; Ling, T.T.; Lamming, D.; Sternberg, S.S.; Roepe, P.D. Human MDR 1 protein overexpression delays the apoptotic cascade in Chinese hamster ovary fibroblasts. Biochemistry., 1997, 36(37), 11169-11178.
151. Young, L.C.; Campling, B.G.; Voskoglou-Nomikos, T.; Cole, S.P.; Deeley, R.G.; Gerlach, J.H. Expression of multidrug resistance protein-related genes in lung cancer: correlation with drug response. Clin. Cancer Res., 1999, 5(3), 673-680.
152. Hoffmeyer, S.; Burk, O.; von Richter, O.; Arnold, H.P.; Brock-moller, J.; Johne, A.; Cascorbi, I.; Gerloff, T.; Roots, I.; Eichelbaum, M.; Brinkmann, U. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc. Natl. Acad. Sci. U S A., 2000, 97(7), 3473-3478.
153. Awasthi, Y.C.; Sharma, R.; Yadav, S.; Dwivedi, S.; Sharma, A.; Awasthi, S. The non-ABC drug transporter RLIP76 (RALBP-1) plays a major role in the mechanisms of drug resistance. Curr. Drug Metab., 2007, 8(4), 315-323.
154. Grzywacz, M.J.; Yang, J.M.; Hait, W.N. Effect of the multidrug resistance protein on the transport of the antiandrogen flutamide. Cancer Res., 2003, 63(10), 2492-2498.
155. Rosso, R.; Dolfini, E.; Donelli, M.G. Prolonged effect of pentobar-bital in tumor bearing rats. Eur. J. Cancer., 1968, 4(1), 133-135.
156. Aguirre, C.; Troconiz, I.F.; Valdivieso, A.; Jimenez, R.M.; Gonzalez, J.P.; Calvo, R.; Rodriguez-Sasiain, J.M. Pharmacokinetics and pharmacodynamics of penbutolol in healthy and cancer subjects: role of altered protein binding. Res. Commun. Mol. Pathol. Pharmacol., 1996, 92(1), 53-72.
157. Williams, M.L.; Bhargava, P.; Cherrouk, I.; Marshall, J.L.; Flockhart, D.A.; Wainer, I.W. A discordance of the cytochrome P450 2C19 genotype and phenotype in patients with advanced cancer. Br. J. Clin. Pharmacol., 2000, 49(5), 485-488.
158. Balkwill, F.; Mantovani, A. Inflammation and cancer: back to Virchow? Lancet., 2001, 357(9255), 539-545.
159. Burke, F.; Balkwill, F.R. Cytokines in animal models of cancer. Biotherapy., 1996, 8(3-4), 229-241.
160. Burke, F.; Relf, M.; Negus, R.; Balkwill, F. A cytokine profile of normal and malignant ovary. Cytokine., 1996, 8(7), 578-585.
161. Yu, L.; Chen, S. Toll-like receptors expressed in tumor cells: targets for therapy. Cancer Immunol. Immunother., 2008, 57(9), 1271-1278.
162. Lind, D.S.; Hochwald, S.N.; Malaty, J.; Rekkas, S.; Hebig, P.; Mishra, G.; Moldawer, L.L.; Copeland, E.M., 3rd; Mackay, S. Nuclear factor-kappa B is upregulated in colorectal cancer. Surgery., 2001, 130(2), 363-369.
163. Karin, M.; Cao, Y.; Greten, F.R.; Li, Z.W. NF-kappaB in cancer: from innocent bystander to major culprit. Nat. Rev. Cancer., 2002, 2(4), 301-310.
164. Wild, S.; Roglic, G.; Green, A.; Sicree, R.; King, H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care., 2004, 27(5), 1047-1053.
165. Shimojo, N.; Ishizaki, T.; Imaoka, S.; Funae, Y.; Fujii, S.; Okuda, K. Changes in amounts of cytochrome P450 isozymes and levels of catalytic activities in hepatic and renal microsomes of rats with streptozocin-induced diabetes. Biochem. Pharmacol., 1993, 46(4), 621-627.
166. Chen, T.L.; Chen, S.H.; Tai, T.Y.; Chao, C.C.; Park, S.S.; Guengerich, F.P.; Ueng, T.H. Induction and suppression of renal and hepatic cytochrome P450-dependent monooxygenases by acute and chronic streptozotocin diabetes in hamsters. Arch. Toxicol., 1996, 70(3-4), 202-208.
167. Sakuma, T.; Honma, R.; Maguchi, S.; Tamaki, H.; Nemoto, N. Different expression of hepatic and renal cytochrome P450s between the streptozotocin-induced diabetic mouse and rat. Xenobiotica., 2001, 31(4), 223-237.
168. Lenzen, S. The mechanisms of alloxan-and streptozotocin-induced diabetes. Diabetologia., 2008, 51(2), 216-226.
169. Dixon, R.L.; Hart, L.G.; Rogers, L.A.; Fouts, J.R. The Metabolism of Drugs by Liver Microsomes from Alloxan-Diabetic Rats: Long Term Diabetes. J. Pharmacol. Exp. Ther., 1963, 142, 312-317.
170. Arinc, E.; Arslan, S.; Adali, O. Differential effects of diabetes on CYP2E1 and CYP2B4 proteins and associated drug metabolizing enzyme activities in rabbit liver. Arch. Toxicol., 2005, 79(8), 427-433.
171. Lee, J.H.; Yang, S.H.; Oh, J.M.; Lee, M.G. Pharmacokinetics of drugs in rats with diabetes mellitus induced by alloxan or streptozocin: comparison with those in patients with type I diabetes mellitus. J. Pharm. Pharmacol., 2010, 62(1), 1-23.
172. Xiong, H.; Yoshinari, K.; Brouwer, K.L.; Negishi, M. Role of constitutive androstane receptor in the in vivo induction of Mrp3 and CYP2B1/2 by phenobarbital. Drug Metab. Dispos., 2002, 30(8), 918-923.
173. Yoshinari, K.; Takagi, S.; Sugatani, J.; Miwa, M. Changes in the expression of cytochromes P450 and nuclear receptors in the liver of genetically diabetic db/db mice. Biol. Pharm. Bull., 2006, 29(8), 1634-1638.
174. Yoshinari, K.; Takagi, S.; Yoshimasa, T.; Sugatani, J.; Miwa, M. Hepatic CYP3A expression is attenuated in obese mice fed a highfat diet. Pharm. Res., 2006, 23(6), 1188-1200.
175. Ghose, R.; Omoluabi, O.; Gandhi, A.; Shah, P.; Strohacker, K.; Carpenter, K.C.; McFarlin, B.; Guo, T. Role of high-fat diet in regulation of gene expression of drug metabolizing enzymes and transporters. Life Sci., 2011, 89(1-2), 57-64.
176. van Waarde, W.M.; Verkade, H.J.; Wolters, H.; Havinga, R.; Baller, J.; Bloks, V.; Muller, M.; Sauer, P.J.; Kuipers, F. Differential effects of streptozotocin-induced diabetes on expression of hepatic ABC-transporters in rats. Gastroenterology., 2002, 122(7), 1842-1852.
177. Cheng, Q.; Aleksunes, L.M.; Manautou, J.E.; Cherrington, N.J.; Scheffer, G.L.; Yamasaki, H.; Slitt, A.L. Drug-metabolizing enzyme and transporter expression in a mouse model of diabetes and obesity. Mol. Pharm., 2008, 5(1), 77-91.
178. Liu, Y.; Liu, H.; Yang, J.; Liu, X.; Lu, S.; Wen, T.; Xie, L.; Wang, G. Increased amyloid beta-peptide (1-40) level in brain of strepto-zotocin-induced diabetic rats. Neuroscience., 2008, 153(3), 796-802.
179. Liu, Y.C.; Liu, H.Y.; Yang, H.W.; Wen, T.; Shang, Y.; Liu, X.D.; Xie, L.; Wang, G.J. Impaired expression and function of breast cancer resistance protein (Bcrp) in brain cortex of streptozocin-induced diabetic rats. Biochem Pharmacol., 2007, 74(12), 1766-1772.
180. Reichel, V.; Burghard, S.; John, I.; Huber, O. P-glycoprotein and breast cancer resistance protein expression and function at the blood-brain barrier and blood-cerebrospinal fluid barrier (choroid plexus) in streptozotocin-induced diabetes in rats. Brain Res., 2011, 1370, 238-245.
181. Maeng, H.J.; Kim, M.H.; Jin, H.E.; Shin, S.M.; Tsuruo, T.; Kim, S.G.; Kim, D.D.; Shim, C.K.; Chung, S.J. Functional induction of P-glycoprotein in the blood-brain barrier of streptozotocin-induced diabetic rats: evidence for the involvement of nuclear factor-kappaB, a nitrosative stress-sensitive transcription factor, in the regulation. Drug Metab. Dispos., 2007, 35(11), 1996-2005.
182. Cressman, A.M.; Petrovic, V.; Piquette-Miller, M. Inflammation-mediated changes in drug transporter expression/activity: implications for therapeutic drug response. Expert Rev. Clin. Pharmacol., 2012, 5(1), 69-89.
183. Wu, K.C.; Pan, H.J.; Yin, H.S.; Chen, M.R.; Lu, S.C.; Lin, C.J. Change in P-glycoprotein and caveolin protein expression in brain striatum capillaries in New Zealand obese mice with type 2 diabetes. Life Sci., 2009, 85(23-26), 775-781.
184. Abernethy, D.R.; Greenblatt, D.J.; Divoll, M.; Shader, R.I. Enhanced glucuronide conjugation of drugs in obesity: studies of lorazepam, oxazepam, and acetaminophen. J. Lab. Clin. Med., 1983, 101(6), 873-880.
185. O'Shea, D.; Davis, S.N.; Kim, R.B.; Wilkinson, G.R. Effect of fasting and obesity in humans on the 6-hydroxylation of chlorzoxa-zone: a putative probe of CYP2E1 activity. Clin. Pharmacol. Ther., 1994, 56(4), 359-367.
186. Watkins, J.B., 3rd; Sherman, S.E. Long-term diabetes alters the hepatobiliary clearance of acetaminophen, bilirubin and digoxin. J. Pharmacol. Exp. Ther., 1992, 260(3), 1337-1343.
187. Park, J.H.; Lee, W.I.; Yoon, W.H.; Park, Y.D.; Lee, J.S.; Lee, M.G. Pharmacokinetic and pharmacodynamic changes of furosemide after intravenous and oral administration to rats with alloxan-induced diabetes mellitus. Biopharm. Drug Dispos., 1998, 19(6), 357-364.
188. Park, J.M.; Moon, C.H.; Lee, M.G. Pharmacokinetic changes of methotrexate after intravenous administration to streptozotocin-induced diabetes mellitus rats. Res. Commun. Mol. Pathol. Pharmacol., 1996, 93(3), 343-352.
189. Baek, H.W.; Bae, S.K.; Lee, M.G.; Sohn, Y.T. Pharmacokinetics of chlorzoxazone in rats with diabetes: Induction of CYP2E1 on 6- hydroxychlorzoxazone formation. J. Pharm. Sci., 2006, 95(11), 2452-2462.
190. Cook, A.M.; Martin, C.; Adams, V.R.; Morehead, R.S. Pharmacokinetics of intravenous levofloxacin administered at 750 milli - grams in obese adults. Antimicrob. Agents Chemother., 2011, 55(7), 3240-3243.
191. Varin, F.; Ducharme, J.; Theoret, Y.; Besner, J.G.; Bevan, D.R.; Donati, F. Influence of extreme obesity on the body disposition and neuromuscular blocking effect of atracurium. Clin. Pharmacol. Ther., 1990, 48(1), 18-25.
192. Derry, C.L.; Kroboth, P.D.; Pittenger, A.L.; Kroboth, F.J.; Corey, S.E.; Smith, R.B. Pharmacokinetics and pharmacodynamics of triazolam after two intermittent doses in obese and normal-weight men. J. Clin. Psychopharmacol., 1995, 15(3), 197-205.
193. Hotamisligil, G.S.; Shargill, N.S.; Spiegelman, B.M. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science., 1993, 259(5091), 87-91.
194. Wellen, K.E.; Hotamisligil, G.S. Inflammation, stress, and diabetes. J Clin Invest. 2005, 115(5), 1111-1119.
195. Thummel, K.E.; Schenkman, J.B. Effects of testosterone and growth hormone treatment on hepatic microsomal P450 expression in the diabetic rat. Mol. Pharmacol., 1990, 37(1), 119-129.
196. Lucas, D.; Farez, C.; Bardou, L.G.; Vaisse, J.; Attali, J.R.; Valensi, P. Cytochrome P450 2E1 activity in diabetic and obese patients as assessed by chlorzoxazone hydroxylation. Fundam. Clin. Pharmacol., 1998, 12(5), 553-558.
197. De Waziers, I.; Garlatti, M.; Bouguet, J.; Beaune, P.H.; Barouki, R. Insulin down-regulates cytochrome P450 2B and 2E expression at the post-transcriptional level in the rat hepatoma cell line. Mol. Pharmacol., 1995, 47(3), 474-479.
198. Woodcroft, K.J.; Hafner, M.S.; Novak, R.F. Insulin signaling in the transcriptional and posttranscriptional regulation of CYP2E1 expression. Hepatology., 2002, 35(2), 263-273.
199. Kim, S.K.; Novak, R.F. The role of intracellular signaling in insulin-mediated regulation of drug metabolizing enzyme gene and protein expression. Pharmacol. Ther., 2007, 113(1), 88-120.
200. Chua, S.C., Jr.; White, D.W.; Wu-Peng, X.S.; Liu, S.M.; Okada, N.; Kershaw, E.E.; Chung, W.K.; Power-Kehoe, L.; Chua, M.; Tartaglia, L.A.; Leibel, R.L. Phenotype of fatty due to Gln269Pro mutation in the leptin receptor (Lepr). Diabetes., 1996, 45(8), 1141-1143.
201. Lee, G.H.; Proenca, R.; Montez, J.M.; Carroll, K.M.; Darvishzadeh, J.G.; Lee, J.I.; Friedman, J.M. Abnormal splicing of the leptin receptor in diabetic mice. Nature., 1996, 379(6566), 632-635.
202. Ali, R.; Cusi, K. New diagnostic and treatment approaches in nonalcoholic fatty liver disease (NAFLD). Ann. Med., 2009, 41(4), 265-278.
203. Clark, J.M.; Brancati, F.L.; Diehl, A.M. The prevalence and etiology of elevated aminotransferase levels in the United States. Am. J. Gastroenterol., 2003, 98(5), 960-967.
204. Reynaert, H.; Geerts, A.; Henrion, J. Review article: the treatment of non-alcoholic steatohepatitis with thiazolidinediones. Aliment Pharmacol. Ther., 2005, 22(10), 897-905.
205. Weltman, M.D.; Farrell, G.C.; Hall, P.; Ingelman-Sundberg, M.; Liddle, C. Hepatic cytochrome P450 2E1 is increased in patients with nonalcoholic steatohepatitis. Hepatology., 1998, 27(1), 128-133.
206. Fisher, C.D.; Jackson, J.P.; Lickteig, A.J.; Augustine, L.M.; Cherrington, N.J. Drug metabolizing enzyme induction pathways in experimental non-alcoholic steatohepatitis. Arch. Toxicol., 2008, 82(12), 959-964.
207. Fisher, C.D.; Lickteig, A.J.; Augustine, L.M.; Ranger-Moore, J.; Jackson, J.P.; Ferguson, S.S.; Cherrington, N.J. Hepatic cytochrome P450 enzyme alterations in humans with progressive stages of nonalcoholic fatty liver disease. Drug Metab. Dispos., 2009, 37(10), 2087-2094.
208. Rinella, M.E.; Green, R.M. The methionine-choline deficient dietary model of steatohepatitis does not exhibit insulin resistance. J. Hepatol., 2004, 40(1), 47-51.
209. Yamaguchi, K.; Yang, L.; McCall, S.; Huang, J.; Yu, X.X.; Pandey, S.K.; Bhanot, S.; Monia, B.P.; Li, Y.X.; Diehl, A.M. Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitis. Hepatology., 2007, 45(6), 1366-1374.
210. Lickteig, A.J. Drug metabolizing enzyme, drug transporter expression and drug disposition are altered in models of inflammatory liver disease. PhD Thesis, The University of Arizona, Tucson, December 2007.
211. Weltman, M.D.; Farrell, G.C.; Liddle, C. Increased hepatocyte CYP2E1 expression in a rat nutritional model of hepatic steatosis with inflammation. Gastroenterology., 1996, 111(6), 1645-1653.
212. Zhang, W.V.; Ramzan, I.; Murray, M. Impaired microsomal oxidation of the atypical antipsychotic agent clozapine in hepatic steatosis. J. Pharmacol. Exp. Ther., 2007, 322(2), 770-777.
213. Gomez-Lechon, M.J.; Donato, M.T.; Castell, J.V.; Jover, R. Human hepatocytes in primary culture: the choice to investigate drug metabolism in man. Curr. Drug. Metab., 2004, 5(5), 443-462.
214. Donato, M.T.; Jimenez, N.; Serralta, A.; Mir, J.; Castell, J.V.; Gomez-Lechon, M.J. Effects of steatosis on drug-metabolizing capability of primary human hepatocytes. Toxicol. In vitro., 2007, 21(2), 271-276.
215. Merrell, M.D.; Cherrington, N.J. Drug metabolism alterations in nonalcoholic fatty liver disease. Drug Metab. Rev., 2011, 43(3), 317-334.
216. Hardwick, R.N.; Fisher, C.D.; Canet, M.J.; Lake, A.D.; Cherrington, N.J. Diversity in antioxidant response enzymes in progressive stages of human nonalcoholic fatty liver disease. Drug Metab. Dispos., 2010, 38(12), 2293-2301.
217. Lee, T.Y.; Chang, H.H.; Lo, W.C.; Lin, H.C. Alleviation of hepatic oxidative stress by Chinese herbal medicine Yin-Chen-Hao-Tang in obese mice with steatosis. Int. J. Mol. Med., 2010, 25(6), 837-844.
218. Baker, S.S.; Baker, R.D.; Liu, W.; Nowak, N.J.; Zhu, L. Role of alcohol metabolism in non-alcoholic steatohepatitis. PLoS. One., 2010, 5(3), e9570.
219. Fisher, C.D.; Lickteig, A.J.; Augustine, L.M.; Oude Elferink, R.P.; Besselsen, D.G.; Erickson, R.P.; Cherrington, N.J. Experimental non-alcoholic fatty liver disease results in decreased hepatic uptake transporter expression and function in rats. Eur. J. Pharmacol., 2009, 613(1-3), 119-127.
220. Lickteig, A.J.; Fisher, C.D.; Augustine, L.M.; Aleksunes, L.M.; Besselsen, D.G.; Slitt, A.L.; Manautou, J.E.; Cherrington, N.J. Efflux transporter expression and acetaminophen metabolite excretion are altered in rodent models of nonalcoholic fatty liver disease. Drug Metab. Dispos., 2007, 35(10), 1970-1978.
221. Hardwick, R.N.; Fisher, C.D.; Canet, M.J.; Scheffer, G.L.; Cherrington, N.J. Variations in ATP-binding cassette transporter regulation during the progression of human nonalcoholic fatty liver disease. Drug Metab. Dispos., 2011, 39(12), 2395-2402.
222. Lake, A.D.; Novak, P.; Fisher, C.D.; Jackson, J.P.; Hardwick, R.N.; Billheimer, D.D.; Klimecki, W.T.; Cherrington, N.J. Analysis of global and absorption, distribution, metabolism, and elimination gene expression in the progressive stages of human nonalcoholic fatty liver disease. Drug Metab. Dispos., 2011, 39(10), 1954-1960.
223. Barshop, N.J.; Capparelli, E.V.; Sirlin, C.B.; Schwimmer, J.B.; Lavine, J.E. Acetaminophen pharmacokinetics in children with nonalcoholic fatty liver disease. J. Pediatr. Gastroenterol. Nutr., 2011, 52(2), 198-202.
224. Hardwick, R.N.; Fisher, C.D.; Street, S.M.; Canet, M.J.; Cherrington, N.J. Molecular mechanism of altered ezetimibe disposition in nonalcoholic steatohepatitis. Drug Metab. Dispos., 2012, 40(3), 450-460.
225. Schrieber, S.J.; Wen, Z.; Vourvahis, M.; Smith, P.C.; Fried, M.W.; Kashuba, A.D.; Hawke, R.L. The pharmacokinetics of silymarin is altered in patients with hepatitis C virus and nonalcoholic Fatty liver disease and correlates with plasma caspase-3/7 activity. Drug Metab. Dispos., 2008, 36(9), 1909-1916.
226. Li, P.; Robertson, T.A.; Thorling, C.A.; Zhang, Q.; Fletcher, L.M.; Crawford, D.H.; Roberts, M.S. Hepatic pharmacokinetics of cationic drugs in a high-fat emulsion-induced rat model of nonalcoholic steatohepatitis. Drug Metab. Dispos., 2011, 39(4), 571-579.
227. Donato, M.T.; Lahoz, A.; Jimenez, N.; Perez, G.; Serralta, A.; Mir, J.; Castell, J.V.; Gomez-Lechon, M.J. Potential impact of steatosis on cytochrome P450 enzymes of human hepatocytes isolated from fatty liver grafts. Drug Metab. Dispos., 2006, 34(9), 1556-1562.
228. Lickteig, A.J.; Fisher, C.D.; Augustine, L.M.; Cherrington, N.J. Genes of the antioxidant response undergo upregulation in a rodent model of nonalcoholic steatohepatitis. J. Biochem. Mol. Toxicol., 2007, 21(4), 216-220.
229. Ai, Z.L.; Zhu, C.H.; Min, M.; Wang, J.; Lan, C.H.; Fan, L.L.; Sun, W.J.; Chen, D.F. The role of hepatic liver X receptor alpha-and sterol regulatory element binding protein-1c-mediated lipid disorder in the pathogenesis of non-alcoholic steatohepatitis in rats. J. Int. Med. Res., 2011, 39(4), 1219-1229.
230. Gnerre, C.; Schuster, G.U.; Roth, A.; Handschin, C.; Johansson, L.; Looser, R.; Parini, P.; Podvinec, M.; Robertsson, K.; Gustafsson, J.A.; Meyer, U.A. LXR deficiency and cholesterol feeding affect the expression and phenobarbital-mediated induction of cytochromes P450 in mouse liver. J. Lipid Res., 2005, 46(8), 1633-1642.
231. Uppal, H.; Saini, S.P.; Moschetta, A.; Mu, Y.; Zhou, J.; Gong, H.; Zhai, Y.; Ren, S.; Michalopoulos, G.K.; Mangelsdorf, D.J.; Xie, W. Activation of LXRs prevents bile acid toxicity and cholestasis in female mice. Hepatology., 2007, 45(2), 422-432.
232. Gong, H.; Guo, P.; Zhai, Y.; Zhou, J.; Uppal, H.; Jarzynka, M.J.; Song, W.C.; Cheng, S.Y.; Xie, W. Estrogen deprivation and inhibition of breast cancer growth in vivo through activation of the orphan nuclear receptor liver X receptor. Mol. Endocrinol., 2007, 21(8), 1781-1790.
233. Ip, E.; Farrell, G.C.; Robertson, G.; Hall, P.; Kirsch, R.; Leclercq, I. Central role of PPARalpha-dependent hepatic lipid turnover in dietary steatohepatitis in mice. Hepatology., 2003, 38(1), 123-132.
234. Ip, E.; Farrell, G.; Hall, P.; Robertson, G.; Leclercq, I. Administration of the potent PPARalpha agonist, Wy-14,643, reverses nutritional fibrosis and steatohepatitis in mice. Hepatology., 2004, 39(5), 1286-1296.
235. Yu, S.; Matsusue, K.; Kashireddy, P.; Cao, W.Q.; Yeldandi, V.; Yeldandi, A.V.; Rao, M.S.; Gonzalez, F.J.; Reddy, J.K. Adipocyte-specific gene expression and adipogenic steatosis in the mouse liver due to peroxisome proliferator-activated receptor gamma1 (PPARgamma1) overexpression. J. Biol. Chem., 2003, 278(1), 498-505.
236. Gavrilova, O.; Haluzik, M.; Matsusue, K.; Cutson, J.J.; Johnson, L.; Dietz, K.R.; Nicol, C.J.; Vinson, C.; Gonzalez, F.J.; Reitman, M.L. Liver peroxisome proliferator-activated receptor gamma contributes to hepatic steatosis, triglyceride clearance, and regulation of body fat mass. J. Biol. Chem., 2003, 278(36), 34268-34276.
237. Moran-Salvador, E.; Lopez-Parra, M.; Garcia-Alonso, V.; Titos, E.; Martinez-Clemente, M.; Gonzalez-Periz, A.; Lopez-Vicario, C.; Barak, Y.; Arroyo, V.; Claria, J. Role for PPARgamma in obesity-induced hepatic steatosis as determined by hepatocyte-and macro-phage-specific conditional knockouts. Faseb. J., 2011, 25(8), 2538-2550.
238. Wu, C.W.; Chu, E.S.; Lam, C.N.; Cheng, A.S.; Lee, C.W.; Wong, V.W.; Sung, J.J.; Yu, J. PPARgamma is essential for protection against nonalcoholic steatohepatitis. Gene Ther., 2010, 17(6), 790-798.
239. Neuschwander-Tetri, B.A.; Brunt, E.M.; Wehmeier, K.R.; Oliver, D.; Bacon, B.R. Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-gamma ligand rosiglitazone. Hepatology., 2003, 38(4), 1008-1017.
240. Lutchman, G.; Promrat, K.; Kleiner, D.E.; Heller, T.; Ghany, M.G.; Yanovski, J.A.; Liang, T.J.; Hoofnagle, J.H. Changes in serum adipokine levels during pioglitazone treatment for nonalcoholic steatohepatitis: relationship to histological improvement. Clin. Gastroenterol. Hepatol., 2006, 4(8), 1048-1052.
241. Ratziu, V.; Giral, P.; Jacqueminet, S.; Charlotte, F.; Hartemann-Heurtier, A.; Serfaty, L.; Podevin, P.; Lacorte, J.M.; Bernhardt, C.; Bruckert, E.; Grimaldi, A.; Poynard, T. Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled Fatty Liver Improvement with Rosiglitazone Therapy (FLIRT) Trial. Gastroenterology., 2008, 135(1), 100-110.
242. van den Bosch, H.M.; Bunger, M.; de Groot, P.J.; van der Meijde, J.; Hooiveld, G.J.; Muller, M. Gene expression of transporters and phase I/II metabolic enzymes in murine small intestine during fasting. BMC. Genomics., 2007, 8, 267.
243. Xu, C.; Li, C.Y.; Kong, A.N. Induction of phase I, II and III drug metabolism/transport by xenobiotics. Arch. Pharm. Res., 2005, 28(3), 249-268.
244. Desvergne, B.; Wahli, W. Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocr. Rev., 1999, 20(5), 649-688.
245. Wang, Y.; Ausman, L.M.; Russell, R.M.; Greenberg, A.S.; Wang, X.D. Increased apoptosis in high-fat diet-induced nonalcoholic steatohepatitis in rats is associated with c-Jun NH2-terminal kinase activation and elevated proapoptotic Bax. J. Nutr., 2008, 138(10), 1866-1871.
246. Abernethy, D.R.; Flockhart, D.A. Molecular basis of cardiovascular drug metabolism: implications for predicting clinically important drug interactions. Circulation., 2000, 101(14), 1749-1753.
247. Young, M.J.; Clyne, C.D.; Cole, T.J.; Funder, J.W. Cardiac steroi-dogenesis in the normal and failing heart. J. Clin. Endocrinol. Metab., 2001, 86(11), 5121-5126.
248. Tan, F.L.; Moravec, C.S.; Li, J.; Apperson-Hansen, C.; McCarthy, P.M.; Young, J.B.; Bond, M. The gene expression fingerprint of human heart failure. Proc. Natl. Acad. Sci. U S A., 2002, 99(17), 11387-11392.
249. Satoh, M.; Nakamura, M.; Saitoh, H.; Satoh, H.; Akatsu, T.; Iwasaka, J.; Masuda, T.; Hiramori, K. Aldosterone synthase (CYP11B2) expression and myocardial fibrosis in the failing human heart. Clin. Sci. (Lond)., 2002, 102(4), 381-386.
250. Thum, T.; Borlak, J. Testosterone, cytochrome P450, and cardiac hypertrophy. FASEB. J., 2002, 16(12), 1537-1549.
251. Johnston, S.C. Ischemic preconditioning from transient ischemic attacks? Data from the Northern California TIA Study. Stroke., 2004, 35(11 Suppl 1), 2680-2682.
252. Kivisto, K.T.; Niemi, M.; Schaeffeler, E.; Pitkala, K.; Tilvis, R.; Fromm, M.F.; Schwab, M.; Lang, F.; Eichelbaum, M.; Strandberg, T. CYP3A5 genotype is associated with diagnosis of hypertension in elderly patients: data from the DEBATE Study. Am. J. Pharmacogenomics., 2005, 5(3), 191-195.
253. *3 allele on pharmacokinetics and pharmacodynamics of losartan in healthy Japanese subjects. Eur. J. Clin. Pharmacol., 2003, 59(8-9), 589-592.
254. Tortorici, M.A.; Mu, Y.; Kochanek, P.M.; Xie, W.; Poloyac, S.M. Moderate hypothermia prevents cardiac arrest-mediated suppression of drug metabolism and induction of interleukin-6 in rats. Crit. Care Med., 2009, 37(1), 263-269.
255. Grube, M.; Ameling, S.; Noutsias, M.; Kock, K.; Triebel, I.; Bonitz, K.; Meissner, K.; Jedlitschky, G.; Herda, L.R.; Reinthaler, M.; Rohde, M.; Hoffmann, W.; Kuhl, U.; Schultheiss, H.P.; Volker, U.; Felix, S.B.; Klingel, K.; Kandolf, R.; Kroemer, H.K. Selective regulation of cardiac organic cation transporter novel type 2 (OCTN2) in dilated cardiomyopathy. Am. J. Pathol., 2011, 178(6), 2547-2559.
256. Solbach, T.F.; Paulus, B.; Weyand, M.; Eschenhagen, T.; Zolk, O.; Fromm, M.F. ATP-binding cassette transporters in human heart failure. Naunyn Schmiedebergs Arch. Pharmacol., 2008, 377(3), 231-243.
257. Solbach, T.F.; Grube, M.; Fromm, M.F.; Zolk, O. Organic cation transporter 3: expression in failing and nonfailing human heart and functional characterization. J. Cardiovasc. Pharmacol., 2011, 58(4), 409-417.
258. Dazert, P.; Meissner, K.; Vogelgesang, S.; Heydrich, B.; Eckel, L.; Bohm, M.; Warzok, R.; Kerb, R.; Brinkmann, U.; Schaeffeler, E.; Schwab, M.; Cascorbi, I.; Jedlitschky, G.; Kroemer, H.K. Expression and localization of the multidrug resistance protein 5 (MRP5/ABCC5), a cellular export pump for cyclic nucleotides, in human heart. Am. J. Pathol., 2003, 163(4), 1567-1577.
259. Meissner, K.; Sperker, B.; Karsten, C.; Meyer Zu Schwabedissen, H.; Seeland, U.; Bohm, M.; Bien, S.; Dazert, P.; Kunert-Keil, C.; Vogelgesang, S.; Warzok, R.; Siegmund, W.; Cascorbi, I.; Wendt, M.; Kroemer, H.K. Expression and localization of P-glycoprotein in human heart: effects of cardiomyopathy. J. Histochem. Cytochem., 2002, 50(10), 1351-1356.
260. Meissner, K.; Heydrich, B.; Jedlitschky, G.; Meyer Zu Schwabedissen, H.; Mosyagin, I.; Dazert, P.; Eckel, L.; Vogelgesang, S.; Warzok, R.W.; Bohm, M.; Lehmann, C.; Wendt, M.; Cascorbi, I.; Kroemer, H.K. The ATP-binding cassette transporter ABCG2 (BCRP), a marker for side population stem cells, is expressed in human heart. J. Histochem. Cytochem., 2006, 54(2), 215-221.
261. Thomson, P.D.; Rowland, M.; Melmon, K.L. The influence of heart failure, liver disease, and renal failure on the disposition of lidocaine in man. Am. Heart J., 1971, 82(3), 417-421.
262. Prescott, L.F.; Adjepon-Yamoah, K.K.; Talbot, R.G. Impaired Lignocaine metabolism in patients with myocardial infarction and cardiac failure. Br. Med. J., 1976, 1(6015), 939-941.
263. Carmona, M.J.; Pereira, V.A.; Malbouisson, L.M.; Auler, J.O., Jr.; Santos, S.R. Effect of cardiopulmonary bypass on the pharmacokinetics of propranolol and atenolol. Braz. J. Med. Biol. Res., 2009, 42(6), 574-581.
264. Fliser, D.; Buchholz, K.; Haller, H. Antiinflammatory effects of angiotensin II subtype 1 receptor blockade in hypertensive patients with microinflammation. Circulation., 2004, 110(9), 1103-1107.
265. Frye, R.F.; Schneider, V.M.; Frye, C.S.; Feldman, A.M. Plasma levels of TNF-alpha and IL-6 are inversely related to cytochrome P450-dependent drug metabolism in patients with congestive heart failure. J. Card. Fail., 2002, 8(5), 315-319.
266. Harris, M. Careers in nursing: caring for children with rheumatoid arthritis. Nursing (Lond)., 1980, 20, 880-881.
267. Cawthorne, M.A.; Palmer, E.D.; Green, J. Adjuvant-induced arthritis and drug-metabolizing enzymes. Biochem. Pharmacol., 1976, 25(24), 2683-2688.
268. Hung, D.Y.; Siebert, G.A.; Chang, P.; Whitehouse, M.W.; Fletcher, L.; Crawford, D.H.; Roberts, M.S. Hepatic pharmacokinetics of propranolol in rats with adjuvant-induced systemic inflammation. Am. J. Physiol. Gastrointest. Liver Physiol., 2006, 290(2), G343-351.
269. Projean, D.; Dautrey, S.; Vu, H.K.; Groblewski, T.; Brazier, J.L.; Ducharme, J. Selective downregulation of hepatic cytochrome P450 expression and activity in a rat model of inflammatory pain. Pharm. Res., 2005, 22(1), 62-70.
270. Uno, S.; Kawase, A.; Tsuji, A.; Tanino, T.; Iwaki, M. Decreased intestinal CYP3A and P-glycoprotein activities in rats with adjuvant arthritis. Drug Metab. Pharmacokinet., 2007, 22(4), 313-321.
271. O'Dell, J.R. Therapeutic strategies for rheumatoid arthritis. N. Engl. J. Med., 2004, 350(25), 2591-2602.
272. Wang, Y.; Fang, Y.; Huang, W.; Zhou, X.; Wang, M.; Zhong, B.; Peng, D. Effect of sinomenine on cytokine expression of macrophages and synoviocytes in adjuvant arthritis rats. J. Ethnopharmacol., 2005, 98(1-2), 37-43.
273. Dickmann, L.J.; McBride, H.J.; Patel, S.K.; Miner, K.; Wienkers, L.C.; Slatter, J.G. Murine collagen antibody induced arthritis (CAIA) and primary mouse hepatocyte culture as models to study cytochrome P450 suppression. Biochem. Pharmacol., 2012,
274. Ferrari, L.; Jouzeau, J.Y.; Gillet, P.; Herber, R.; Fener, P.; Batt, A.M.; Netter, P. Interleukin-1 beta differentially represses drugmetabolizing enzymes in arthritic female rats. J. Pharmacol. Exp. Ther., 1993, 264(2), 1012-1020.
275. Achira, M.; Totsuka, R.; Fujimura, H.; Kume, T. Tissue-specific regulation of expression and activity of P-glycoprotein in adjuvant arthritis rats. Eur. J. Pharm. Sci., 2002, 16(1-2), 29-36.
276. Achira, M.; Totsuka, R.; Kume, T. Decreased activity of hepatic P-glycoprotein in the isolated perfused liver of the adjuvant arthritis rat. Xenobiotica., 2002, 32(11), 963-973.
277. Uno, S.; Uraki, M.; Ito, A.; Shinozaki, Y.; Yamada, A.; Kawase, A.; Iwaki, M. Changes in mRNA expression of ABC and SLC transporters in liver and intestines of the adjuvant-induced arthritis rat. Biopharm. Drug Dispos., 2009, 30(1), 49-54.
278. Diamanti, A.P.; Rosado, M.; Germano, V.; Scarsella, M.; Giorda, E.; Podesta, E.; D'Amelio, R.; Carsetti, R.; Lagana, B. Reversion of resistance to immunosuppressive agents in three patients with psoriatic arthritis by cyclosporine A: modulation of P-glycoprotein function. Clin. Immunol., 2011, 138(1), 9-13.
279. Honjo, K.; Takahashi, K.A.; Mazda, O.; Kishida, T.; Shinya, M.; Tokunaga, D.; Arai, Y.; Inoue, A.; Hiraoka, N.; Imanishi, J.; Kubo, T. MDR1a/1b gene silencing enhances drug sensitivity in rat fibroblast-like synoviocytes. J. Gene. Med., 2010, 12(2), 219-227.
280. van der Heijden, J.W.; Oerlemans, R.; Tak, P.P.; Assaraf, Y.G.; Kraan, M.C.; Scheffer, G.L.; van der Laken, C.J.; Lems, W.F.; Scheper, R.J.; Dijkmans, B.A.; Jansen, G. Involvement of breast cancer resistance protein expression on rheumatoid arthritis synovial tissue macrophages in resistance to methotrexate and le-flunomide. Arthritis Rheum., 2009, 60(3), 669-677.
281. Tsujimura, S.; Saito, K.; Nawata, M.; Nakayamada, S.; Tanaka, Y. Overcoming drug resistance induced by P-glycoprotein on lymphocytes in patients with refractory rheumatoid arthritis. Ann. Rheum. Dis., 2008, 67(3), 380-388.
282. Dipasquale, G.; Welaj, P.; Rassaert, C.L. Prolonged pentobarbital sleeping time in adjuvant-induced polyarthritic rats. Res. Commun. Chem. Pathol. Pharmacol., 1974, 9(2), 253-264.
283. Piquette-Miller, M.; Jamali, F. Selective effect of adjuvant arthritis on the disposition of propranolol enantiomers in rats detected using a stereospecific HPLC assay. Pharm. Res., 1993, 10(2), 294-299.
284. Achira, M.; Totsuka, R.; Fujimura, H.; Kume, T. Decreased hepatobiliary transport of methotrexate in adjuvant arthritis rats. Xenobiotica., 2002, 32(12), 1151-1160.
285. Sattari, S.; Dryden, W.F.; Eliot, L.A.; Jamali, F. Despite increased plasma concentration, inflammation reduces potency of calcium channel antagonists due to lower binding to the rat heart. Br. J. Pharmacol., 2003, 139(5), 945-954.
286. Shore, S.A.; Laporte, J.; Hall, I.P.; Hardy, E.; Panettieri, R.A., Jr. Effect of IL-1 beta on responses of cultured human airway smooth muscle cells to bronchodilator agonists. Am. J. Respir. Cell Mol. Biol., 1997, 16(6), 702-712.
287. Laporte, J.D.; Moore, P.E.; Panettieri, R.A.; Moeller, W.; Heyder, J.; Shore, S.A. Prostanoids mediate IL-1beta-induced beta-adrenergic hyporesponsiveness in human airway smooth muscle cells. Am. J. Physiol., 1998, 275(3 Pt 1), L491-501.
288. Schmith, V.D.; Foss, J.F. Inflammation: planning for a source of pharmacokinetic/pharmacodynamic variability in translational studies. Clin. Pharmacol. Ther., 2010, 87(4), 488-491.
289. Shibata, N.; Shimakawa, H.; Minouchi, T.; Yamaji, A. Pharmacokinetics of cyclosporin A after intravenous administration to rats in various disease states. Biol. Pharm. Bull., 1993, 16(11), 1130-1135.
290. Piquette-Miller, M.; Jamali, F. Effect of adjuvant arthritis on the disposition of acebutolol enantiomers in rats. Agents Actions., 1992, 37(3-4), 290-296.
291. Williams, R.O.; Feldmann, M.; Maini, R.N. Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis. Proc. Natl. Acad. Sci. U S A., 1992, 89(20), 9784-9788.
292. Philippe, L.; Gegout-Pottie, P.; Guingamp, C.; Bordji, K.; Terlain, B.; Netter, P.; Gillet, P. Relations between functional, inflammatory, and degenerative parameters during adjuvant arthritis in rats. Am. J. Physiol., 1997, 273(4 Pt 2), R1550-1556.
293. Handel, M.L.; McMorrow, L.B.; Gravallese, E.M. Nuclear factorkappa B in rheumatoid synovium. Localization of p50 and p65. Arthritis Rheum., 1995, 38(12), 1762-1770.
294. Mor, A.; Abramson, S.B.; Pillinger, M.H. The fibroblast-like synovial cell in rheumatoid arthritis: a key player in inflammation and joint destruction. Clin. Immunol., 2005, 115(2), 118-128.
295. Seino, D.; Tokunaga, A.; Tachibana, T.; Yoshiya, S.; Dai, Y.; Obata, K.; Yamanaka, H.; Kobayashi, K.; Noguchi, K. The role of ERK signaling and the P2X receptor on mechanical pain evoked by movement of inflamed knee joint. Pain., 2006, 123(1-2), 193-203.
296. Vergne-Salle, P.; Leger, D.Y.; Bertin, P.; Treves, R.; Beneytout, J.L.; Liagre, B. Effects of the active metabolite of leflunomide, A77 1726, on cytokine release and the MAPK signalling pathway in human rheumatoid arthritis synoviocytes. Cytokine., 2005, 31(5), 335-348.
297. Kawase, A.; Yoshida, I.; Tsunokuni, Y.; Iwaki, M. Decreased PXR and CAR inhibit transporter and CYP mRNA Levels in the liver and intestine of mice with collagen-induced arthritis. Xenobiotica., 2007, 37(4), 366-374.
298. Kawase, A.; Tsunokuni, Y.; Iwaki, M. Effects of alterations in CAR on bilirubin detoxification in mouse collagen-induced arthritis. Drug Metab. Dispos., 2007, 35(2), 256-261.
299. Drozdzik, M.; Rudas, T.; Pawlik, A.; Kurzawski, M.; Czerny, B.; Gornik, W.; Herczynska, M. The effect of 3435C>T MDR1 gene polymorphism on rheumatoid arthritis treatment with disease-modifying antirheumatic drugs. Eur. J. Clin. Pharmacol., 2006, 62(11), 933-937.
300. Takatori, R.; Takahashi, K.A.; Tokunaga, D.; Hojo, T.; Fujioka, M.; Asano, T.; Hirata, T.; Kawahito, Y.; Satomi, Y.; Nishino, H.; Tanaka, T.; Hirota, Y.; Kubo, T. ABCB1 C3435T polymorphism influences methotrexate sensitivity in rheumatoid arthritis patients. Clin. Exp. Rheumatol., 2006, 24(5), 546-554.